Clinical Trials for Ovarian Cancer

A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer with high FRα expression (≥75% cells ≥2+ by VENTANA FOLR1), both platinum-sensitive and -resistant (not primary refractory), receive mirvetuximab soravtansine (FRα-targeted antibody–drug conjugate delivering DM4) IV q3w. Patients are randomized to ocular AE prophylaxis with prednisolone acetate eye drops vs brimonidine, with serial ophthalmic assessments; key exclusions include significant ocular disease, >Grade 1 neuropathy, prior FRα therapy, and poor baseline vision.

ClinicalTrials.gov ID: NCT06365853

Randomized Phase 2 Trial of Maintenance Oral Etoposide or Observation Following High-dose Chemotherapy for Relapsed Metastatic Germ-Cell Tumor

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with relapsed non-seminomatous germ-cell tumor (including ovarian GCT) who completed two tandem cycles of high-dose chemotherapy with peripheral-blood stem-cell transplant and have nonrising AFP/hCG are randomized to maintenance oral etoposide 50 mg daily versus observation. Etoposide is a cytotoxic topoisomerase II inhibitor used here as low-dose maintenance to reduce micrometastatic relapse risk.

ClinicalTrials.gov ID: NCT04804007

A Phase II Trial of Belzutifan in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm study of oral belzutifan, a selective HIF-2α inhibitor, for adults with recurrent or persistent clear cell ovarian carcinoma (≥50% clear cell if mixed) with measurable disease after at least one prior platinum regimen; prior bevacizumab and immunotherapy allowed and treated/stable brain metastases permitted. Patients receive daily belzutifan in 28-day cycles until progression/toxicity, with primary endpoints of ORR and 6-month PFS; class-toxicities include anemia and hypoxia.

ClinicalTrials.gov ID: NCT06677190

A Phase 2, Open-label, Single-arm Study Of Autologous Memory Cytokine Enriched Natural Killer (M-CENK) Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable, recurrent platinum-resistant high-grade ovarian, primary peritoneal, or fallopian tube cancer, ECOG 0–1, and 1–3 prior treatment lines are eligible; prior bevacizumab is required, and patients with BRCA-mutated disease must also have received a PARP inhibitor. Treatment combines gemcitabine with autologous cytokine-enhanced natural killer cells (M-CENK) and N-803, an IL-15 superagonist intended to support natural killer cell activity.

ClinicalTrials.gov ID: NCT06710288

A Phase 1/2, Open-label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Combination With Pembrolizumab (Phase 1 and Phase 2) and Pembrolizumab and Pegylated Liposomal Doxorubicin (Phase 1b) in Patients With Platinum Resistant or Refractory Ovarian Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adult women with recurrent platinum-resistant or refractory ovarian, fallopian tube, or primary peritoneal cancer and disease accessible for local virus administration receive TILT-123 plus pembrolizumab, with pegylated liposomal doxorubicin added in one study group. TILT-123 is an oncolytic adenovirus designed to replicate preferentially in tumor cells and produce TNFα and IL-2 to stimulate antitumor immunity.

ClinicalTrials.gov ID: NCT05271318

Phase II Study Evaluating the Effect of IMNN-001 on Second Look Laparoscopy (SLL) in Combination With Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with newly diagnosed FIGO stage III–IV high-grade serous ovarian, fallopian tube, or primary peritoneal carcinoma who are candidates for neoadjuvant chemotherapy are randomized to carboplatin, paclitaxel, and bevacizumab with or without intraperitoneal IMNN-001, alongside interval surgery and adjuvant therapy. IMNN-001 is an investigational IL-12–encoding plasmid delivered by a lipopolymer nanoparticle to stimulate a local antitumor immune response.

ClinicalTrials.gov ID: NCT05739981

A Phase 2 Study of Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (BELLA)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Platinum‑resistant high‑grade serous or endometrioid epithelial ovarian, primary peritoneal, or fallopian‑tube cancer (1–3 prior lines; prior bevacizumab allowed), ECOG 0–1, measurable disease. Single‑arm regimen adds intermittent relacorilant (selective glucocorticoid receptor modulator to overcome taxane resistance) to nab‑paclitaxel and bevacizumab, given on a 28‑day cycle until progression/toxicity.

ClinicalTrials.gov ID: NCT06906341

A Phase 1b Study of ZN-c3 in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian, Peritoneal, or Fallopian Tube Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: For patients with measurable high-grade serous ovarian, fallopian tube, or primary peritoneal carcinoma after one or two prior lines of therapy for advanced or metastatic disease, this study evaluates azenosertib, an oral WEE1 inhibitor that disrupts the DNA-repair cell-cycle checkpoint. Azenosertib is combined with carboplatin, pegylated liposomal doxorubicin, paclitaxel, gemcitabine, or bevacizumab.

ClinicalTrials.gov ID: NCT04516447

A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with newly diagnosed FIGO stage III–IV high‑grade serous/endometrioid ovarian, fallopian tube, or primary peritoneal cancer with pathogenic BRCA1/2 mutation or HRD+ status after response to first‑line platinum are randomized to maintenance olaparib for 1 year vs 2 years, with optional bevacizumab. Olaparib is an oral PARP1/2 inhibitor exploiting HRD via synthetic lethality; bevacizumab is an anti‑VEGF monoclonal antibody given at physician discretion for up to 1 year.

ClinicalTrials.gov ID: NCT06580314

Combination Therapy With Liposomal Doxorubicin and Withaferin A (Ashwagandha, ASWD) in Recurrent Ovarian Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with platinum-resistant or refractory recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma eligible for single-agent liposomal doxorubicin receive DOXIL 40 mg/m2 q4wk plus daily oral Ashwagandha (withaferin A–rich extract) at the phase I–selected dose. Withaferin A is a multi-target botanical agent (NF-κB inhibition, ER stress induction, cytoskeletal disruption) combined with standard DOXIL to assess safety and early efficacy; excludes prior anthracyclines/liposomal doxorubicin and significant cardiac disease (LVEF ≥55% required).

ClinicalTrials.gov ID: NCT05610735